Optimal Low B-value in Intravoxel Incoherent Motion Diffusion-weighted MR Imaging of the Brain
July 2, 2017 updated by: Tang-Du Hospital
Can the Distribution of Low B-value and the NEX Influence the Pseudodiffusion Parameter Derived From IVIM in Brain?
Our research aims to reveal whether the low b-values distribution and the number of NEX for each b value will influence the accuracy of pseudodiffusion parameter derived from IVIM in brain.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
As an improved MRI technique, diffusion-weighted imaging (DWI) is considered the most sensitive for early pathological changes.
Perfusion measurement has been shown to improve sensitivity and predictive value for tumor grading and prognosis, also as a predicator of recovery with reperfusion in patients of acute ischemic stroke.Our research aims to reveal whether the low b-values distribution and the number of NEX for each b value will influence the accuracy of pseudodiffusion parameter derived from IVIM in brain.
Study Type
Observational
Enrollment (Actual)
20
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 35 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Sampling Method
Probability Sample
Study Population
healthy volunteers
Description
Inclusion Criteria:
- no hypertension or cerebral vascular diseases,
- no systemic metabolic disease;
- no infection or fever;
- no use of corticosteroid drugs;
- no MRI contraindication.
Exclusion Criteria:
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group 1
Low b=(0,50,150,200)，NEX=(1,3,2,2)
|
|
|
Group 2
Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
|
|
|
Group 3
Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
|
|
|
Group 4
Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
|
|
|
Group 5
Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Parameters D* and f in healthy white matter or gray mater
Time Frame: 2-3 days
|
2-3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
December 10, 2014
First Submitted That Met QC Criteria
April 2, 2015
First Posted (Estimate)
April 8, 2015
Study Record Updates
Last Update Posted (Actual)
July 5, 2017
Last Update Submitted That Met QC Criteria
July 2, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TDLL-20140570
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.